U.S. IRS Targets AQR Tax Strategies, Warns of Potential Retroactive Penalties
nashnova research
The US Treasury and IRS jointly issued notices flagging AQR-style "tax alpha" fund strategies for scrutiny, warning that final rules may apply retroactively to completed transactions — putting tens of billions of dollars in tax-strategy assets at risk of reclassification.
What is "tax alpha," and why is the IRS targeting it?
The core technique is a tax-rate mismatch between gains and losses: a fund books profits as capital gains (lower rate) while generating ordinary losses to offset wages, bonuses, and other high-rate income.
In plain terms = you pay tax on your winnings at a discount rate, but deduct your losses at the full rate — the net effect shrinks your tax bill dramatically.
AQR's Delphi Plus fund is the flagship product, with $6.6 billion in assets. In 2025 it generated ordinary losses equal to 28% of invested capital — roughly $2.8 million in deductible losses for every $10 million invested.
Which transaction structures is the IRS examining?
The notice identifies five types that may be designated "listed" or "transactions of interest": tax-aware gain/loss mismatch funds, same-day forex forward contracts (Section 988), selective termination of equity swaps, mixed-character identified straddles, and "box spread" ETFs that simulate Treasury yields without current income.
The IRS drew a line: plain-vanilla long-short equity strategies may qualify as "well-established techniques" and fall outside the scope.
This means → the target is not hedge funds themselves, but structures "primarily tax-motivated rather than driven by genuine investment economics."
What does "retroactive application" mean here?
The most consequential language in the notice: final rules may apply retroactively to transactions already completed.
In plain terms = this is not just "stop doing it from today" — it is "we may also come after what you already did."
AQR previously added disclosure clauses to client documents warning that the IRS might retroactively disallow the tax benefits — but disclosure does not equal immunity; booked tax savings could still be reversed.
How wide is the blast radius?
Nathan Koppikar of short-seller Orso Partners — who has long bet on a regulatory crackdown — calls ordinary-income shielding the industry's "holy grail."
NYU law professor Daniel Hemel compared its potential scale to "carried interest on steroids" — This means → capital-gains harvesting benefits only those who already hold large unrealized gains, but ordinary-income shielding reaches every high-earning doctor, lawyer, and banker, creating a far broader tax base erosion and a larger federal revenue gap.
The public comment period closes October 28; how regulators ultimately classify these structures will determine the fate of tens of billions of dollars in tax-strategy assets.
市场有风险，内容仅供研究参考，不构成投资建议。